

SECTION-1: Identification of the substance / mixture and the company / undertaking

Catalogue Number	CS-O-59745
Product Name	Suzetrigine
CAS No.	2649467-58-1
Category	API
Synonyms	4-((2R,3S,4S,5R)-3-(3,4-difluoro-2-methoxyphenyl)-4,5-dimethyl-5-(trifluoromethyl)tetrahydrofuran-2-carboxamido)picolinamide; Suzetrigine
Brand	Clearsynth Labs Ltd.
Identified uses	Laboratory Chemicals
Uses advised against	Not available
Company	Clearsynth Labs Ltd. Mumbai, India
Emergency Phone #	+91-22-245045900
REACH No.	Not available

SECTION 2: Hazards identification

Disclaimer: This is sample MSDS. Please email sales@clearsynth.com for more details.

2.1 Classification of the substance or mixture-Regulation (EC) No 1272/2008:

Not available

2.2 Label Elements

Signal Word: Not available

Not available

Hazard Statement(s)

Code	Statement
Not available	Not available

Precautionary Statement(s)

Code	Statement
Not available	Not available

SECTION 3: Composition / information on ingredients

3.1 Substance

Component : Suzetrigine

CAS Number : 2649467-58-1

Molecular Formula : C₂₁H₂₀F₅N₃O₄

Molecular Weight : 473.39

Parent Chemical : Suzetrigine

Synonyms : 4-((2R,3S,4S,5R)-3-(3,4-difluoro-2-methoxyphenyl)-4,5-dimethyl-5-(trifluoromethyl)tetrahydrofuran-2-carboxamido)picolinamide; Suzetrigine

Concentration : Not available

SECTION 4: First aid measures

Not available

SECTION 5: Firefighting measures

Not available

SECTION 6: Accidental release measures

Not available

SECTION-7: Handling and storage

Not available

SECTION 8: Exposure controls / personal protection

Not available

SECTION 9: Physical and chemical properties

9.1 Information on basic physical and chemical properties

Test	Result
Appearance	No data available
IR spectrum	No data available
pH	No data available
Solubility	No data available

Property	Value
a) Physical State	No data available
b) Color	No data available
c) Odor	No data available
d) pH	No data available
e) Vapour Pressure	No data available
f) Viscosity	No data available
g) Initial Boiling Point and boiling range	No data available
h) Melting Point / Freezing Point	No data available
i) Auto Ignition Temperature	No data available
j) Flash Point	No data available
k) Explosion Limit, Lower	No data available
l) Explosion Limit, Upper	No data available
m) Decomposition Temperature	No data available
n) Loss on Drying	No data available
o) Relative Density	No data available
p) Solubility (in DMSO)	No data available
q) Oxidizing Properties	No data available

SECTION 10: Stability and reactivity

Not available

SECTION 11: Toxicological information

11.1 Information on toxicological effects

- Acute toxicity: No data available.
- Skin corrosion/irritation: No data available.
- Serious eye damage/eye irritation: No data available.
- Respiratory or skin sensitization: No data available.
- Germ cell mutagenicity: No data available.
- Carcinogenicity: No data available.
- Reproductive toxicity: No data available.
- STOT-single exposure: No data available.
- STOT-repeated exposure: No data available.

- Aspiration hazard: No data available.

Likely routes of exposure

- No data available.

Symptoms related to the physical, chemical and toxicological characteristics

- In the prelicensure trials of suzetrigine, rates of serum aminotransferase elevations during suzetrigine therapy were less than 1% and were generally similar or slightly less than in patients receiving placebo or the combination of acetaminophen and hydrocodone, an active standard regimen of pain control. There were only rare ALT or AST elevations above 5 times the upper limit of normal (ULN) and no elevations of ALT or AST accompanied by jaundice or symptoms. In other uncontrolled studies of suzetrigine used for up to 14 days for both surgical and non-surgical pain, there were no instances of clinically apparent or life-threatening cases of liver injury. Since approval and clinical availability of suzetrigine, there have been no published case reports of clinically apparent liver injury, but clinical experience with its use has been limited. Likelihood score: E (unlikely cause of clinically apparent liver injury).

SECTION 12: Ecological information

Not available

SECTION 13: Disposal considerations

Not available

SECTION 14: Transport information

Not available

SECTION 15: Regulatory information

Not available

SECTION 16: Other information

Not available

DISCLAIMER

This MSDS is system-generated. Please verify and confirm all data, statements, and values with the Support Team before use or distribution.